{Reference Type}: Journal Article
{Title}: Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities.
{Author}: Yu EM;Hwang MW;Aragon-Ching JB;
{Journal}: Res Rep Urol
{Volume}: 15
{Issue}: 0
{Year}: 2023
暂无{DOI}: 10.2147/RRU.S386517
{Abstract}: Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberrant pathway activations of PI3K/AKT due to PTEN loss, epithelial-mesenchymal transition pathways, homologous recombination repair, and DNA repair pathway mechanisms of resistance and cross-talk lead to opportunities for therapeutic targeting in metastatic castration-resistant prostate cancer. This review focuses on mechanisms of progression and key trials that evaluate the drugs and combinations that exploit these pathways.